VF
MLYS icon

Virtu Financial’s Mineralys Therapeutics MLYS Stock Holding History

Virtu Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Buy
+8,886
New +$244K 0.01% 842
2025
Q2 		– Sell
-25,203
Closed -$400K – 1814
2025
Q1 		$400K Buy
+25,203
New +$290K 0.02% 569

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Virtu Financial's MLYS Position: Q2 2026 in Review

Virtu Financial opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 8,886 shares worth $240K. The stake represents 0.01% of the portfolio and ranks #842 among its holdings. This is a return to the name: Virtu Financial previously reported a position in MLYS as recently as Q1 2025.

Virtu Financial first reported a position in MLYS in Q1 2025 and has held it in 2 quarters since. The position peaked at $400K in Q1 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Virtu Financial held 8,886 shares of Mineralys Therapeutics worth $240K as of Q2 2026.
  • Mineralys Therapeutics was a new Virtu Financial position in Q2 2026.
  • Mineralys Therapeutics made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #842 holding.
  • Virtu Financial first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Virtu Financial's Mineralys Therapeutics position peaked at $400K in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.